Information Provided By:
Fly News Breaks for September 13, 2017
Sep 13, 2017 | 08:11 EDT
Canaccord analyst Neil Maruoka assumed coverage of Aurinia Pharmaceuticals and downgraded the stock to Speculative Buy from Buy, citing the high risks associated with biotech drug development. However, he believes the ongoing Phase III AURORA study has a good chance of success and sees Aurinia as undervalued based on the strength of data generated by voclosporin to date. Maruoka set a $10 price target on Aurinia shares.
News For AUPH From the Last 2 Days
There are no results for your query AUPH
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.